PharmaShots | Incisive News in 3 Shots

Subscribe Now

Sentynl Therapeutics

Sentynl Therapeutics’ Nulibry (fosdenopterin) Gains the MHRA’s Approval to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

Sentynl Therapeutics’ Nulibry (fosdenopterin) Gains the MHRA’s Approval to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

April 17, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us